L'afatinib, un nouveau médicament dans le cancer bronchique

Translated title of the contribution: Afatinib, a new drug for lung cancer

Jérôme Sicard, Jean Baptiste Rey, Florian Scotté, Laurent Mortier

Research output: Contribution to journalReview articlepeer-review

Abstract

Afatinib is an irreversible oral tyrosine kinase inhibitor, which blocks the receptors from the ErbB family. Its superiority over leading chemotherapy treatments in terms of progression-free survival and overall survival in patients who are carriers of exon 19 deletion in non small cell lung cancers with EGFR mutations has been proven. Its administration has been associated with side affects found with the class of tyrosine kinase inhibitors, the treatment of which includes preventive and symptomatic measures which must be explained to the patient, along with their impact on compliance with the treatment.

Translated title of the contributionAfatinib, a new drug for lung cancer
Original languageFrench
Pages (from-to)42-45
Number of pages4
JournalActualites Pharmaceutiques
Volume54
Issue number546
DOIs
Publication statusPublished - 1 May 2015
Externally publishedYes

Cite this